We are a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated ocular and systemic diseases. Our lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, and Sjögren-Larsson Syndrome. We have additional product candidates in development for proliferative vitreoretinopathy and other retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer. We’re focused on commercializing our products directly or through collaborations.
We are a publicly-traded company on the Nasdaq exchange, ticker ALDX.